175 related articles for article (PubMed ID: 22513939)
1. Drug treatment for spinal muscular atrophy type I.
Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006281. PubMed ID: 22513939
[TBL] [Abstract][Full Text] [Related]
2. Drug treatment for spinal muscular atrophy type I.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006281. PubMed ID: 22161399
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment for spinal muscular atrophy type I.
Bosboom W; Vrancken AF; van den Berg LH; Wokke J; Iannaccone ST
Cochrane Database Syst Rev; 2009 Jan; (1):CD006281. PubMed ID: 19160274
[TBL] [Abstract][Full Text] [Related]
4. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006282. PubMed ID: 22513940
[TBL] [Abstract][Full Text] [Related]
5. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006282. PubMed ID: 22161400
[TBL] [Abstract][Full Text] [Related]
6. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
7. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment for spinal muscular atrophy types II and III.
Bosboom W; Vrancken AF; van den Berg LH; Wokke JH; Iannaccone ST
Cochrane Database Syst Rev; 2009 Jan; (1):CD006282. PubMed ID: 19160275
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 trial of riluzole in spinal muscular atrophy.
Russman BS; Iannaccone ST; Samaha FJ
Arch Neurol; 2003 Nov; 60(11):1601-3. PubMed ID: 14623733
[TBL] [Abstract][Full Text] [Related]
10. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).
Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431
[TBL] [Abstract][Full Text] [Related]
11. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
12. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Moore DH
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD001447. PubMed ID: 22419278
[TBL] [Abstract][Full Text] [Related]
13. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P;
Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889
[TBL] [Abstract][Full Text] [Related]
15. Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.
Vogel AP; Folker J; Poole ML
Cochrane Database Syst Rev; 2014 Oct; (10):CD008953. PubMed ID: 25348587
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection for treatment of glaucoma in adults.
Sena DF; Lindsley K
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006539. PubMed ID: 28122126
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
18. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
[TBL] [Abstract][Full Text] [Related]
19. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
[TBL] [Abstract][Full Text] [Related]
20. Statins for age-related macular degeneration.
Gehlbach P; Li T; Hatef E
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD006927. PubMed ID: 27490232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
